Clinical Trials Logo

Choroidal Neovascularization clinical trials

View clinical trials related to Choroidal Neovascularization.

Filter by:

NCT ID: NCT00713518 Completed - Clinical trials for Age Related Macular Degeneration

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

MONET
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

NCT ID: NCT00692887 Completed - Clinical trials for Age Related Macular Degeneration

Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)

PHP
Start date: June 2008
Phase: N/A
Study type: Observational

Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence Tomography(OCT). To investigate the Foresee PHP ability to asses treatment progression post treatment.

NCT ID: NCT00679445 Completed - Clinical trials for Wet Age-related Macular Degeneration

A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy

ROSE
Start date: December 2007
Phase: Phase 2
Study type: Interventional

The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.

NCT ID: NCT00604071 Completed - Clinical trials for Age Related Macular Degeneration

Sensitivity of the Home Macular Perimeter (HMP)

HMP
Start date: November 2007
Phase: N/A
Study type: Observational

estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD

NCT ID: NCT00570193 Completed - Clinical trials for Macular Degeneration

Photodynamic and Pharmacologic Treatment of CNV

PBS
Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.

NCT ID: NCT00533520 Completed - Clinical trials for Macular Degeneration

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

BGB/IST
Start date: September 2007
Phase: Phase 4
Study type: Interventional

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

NCT ID: NCT00527475 Completed - Clinical trials for Macular Degeneration

Ranibizumab and Reduced Fluence PDT for AMD

RAP
Start date: May 2007
Phase: Phase 2
Study type: Interventional

Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.

NCT ID: NCT00511706 Completed - Clinical trials for Choroidal Neovascularization

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Start date: November 1, 2007
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00510965 Completed - Clinical trials for Choroidal Neovascularization

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum. 10 patients will receive monthly injections of the drug in one eye over a period of one year.

NCT ID: NCT00504959 Completed - Clinical trials for Subfoveal Choroidal Neovascularization (CNV)

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Start date: July 2007
Phase: Phase 4
Study type: Interventional

This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN